[1] KATAYAMA U N,KIWAMU N,HAYATO G,et al.Neonatal meningitis and recurrent bacteremia with group B Streptococcus transmitted by own mother's milk:A case report and review of previous cases[J].International Journal of Infectious Diseases,2018,74:13-15. [2] KEEFE G P.Streptococcus agalactiae mastitis:A review[J].Canadian Veterinary Journal-revue Veterinaire Canadienne,1997,38(7):429-437. [3] HOLMØY I H,TOFTAKER I,KIRKEBY C,et al.A cohort study of the effect of Streptococcus agalactiae on milk yield and somatic cell count in Norwegian dairy cows[J].Journal of Dairy Science,2019,102(9):8385-8399. [4] CARVALHO-CASTRO G A,SILVA J R,PAIVA L V,et al.Molecular epidemiology of Streptococcus agalactiae isolated from mastitis in Brazilian dairy herds[J].Brazilian Journal of Microbiology,2017,48(3):551-559. [5] MAODA P,LICHANG S,TAO H,et al.Molecular and virulence characterization of highly prevalent Stre-ptococcus agalactiae circulated in bovine dairy herds[J].Veterinary Research,2017,48(1):65. [6] HAENNI M,LUPO A,MADEC J Y.Antimicrobial resistance in Streptococcus spp.[J].Microbiology Spectrum,2018,6(2):1-25. [7] VÉRONIQUE G F,TARDY F,BOUVERON C,et al.Antimicrobial susceptibility of Streptococcus species isolated from clinical mastitis in dairy cows[J].International Journal of Antimicrobial Agents,2002,19(3):219-226. [8] DING Y X,ZHAO J L,HE X L,et al.Antimicrobial resistance and virulence-related genes of Streptococcus obtained from dairy cows with mastitis in Inner Mongolia,China[J].Pharmaceutical Biology,2015,54(1):162-167. [9] RAABE V N,SHANE A L.Group B streptococcus (Streptococcus agalactiae)[J].Microbiology Spectrum,2019,7(2). [10] 马金涛.无乳链球菌奶牛乳房炎分离株的生物被膜形成及调控机制研究[D].合肥:安徽农业大学,2016. MA J T.Formation and regulated mechanism of biofilm in Streptococcus agalactiae isolated from a dairy cow with mastitis[D].Hefei:Anhui Agricultural University,2016.(in Chinese) [11] MYGIND P H,FISCHER R L,SCHNORR K M,et al.Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus[J].Nature,2005,437(7061):975-980. [12] SCHNEIDER T,KRUSE T,WIMMER R,et al.Plectasin,a fungal defensin,targets the bacterial cell wall precursor lipid Ⅱ[J].Science,2010,328(5982):1168-1172. [13] ZHANG Y,TENG D,MAO R Y,et al.High expression of a plectasin-derived peptide NZ2114 in Pichia pastoris and its pharmacodynamics,postantibiotic and synergy against Staphylococcus aureus[J].Applied Microbiology and Biotechnology,2014,98(2):681-694. [14] CHEN H X,MAO R Y,TENG D,et al.Design and pharmacodynamics of recombinant NZ2114 histidine mutants with improved activity against methicillin-resistant Staphylococcus aureus[J].AMB Express,2017,7(1):46. [15] KLEIN K,GRØNNEMOSE R B,ALM M,et al.Controlled release of Plectasin NZ2114 from a hybrid silicone-hydrogel material for inhibition of Staphylococcus aureus biofilm[J].Antimicrobial Agents and Chemotherapy,2017,61(7):AAC.00604-17. [16] WIEGAND I,HILPERT K,HANCOCK R E W.Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances[J].Nature Protocols,2008,3(2):163-175. [17] ZHAO F,YANG N,WANG X M,et al.In vitro/vivo mechanism of action of MP1102 with low/nonresistance against Streptococcus suis type 2 strain CVCC 3928[J].Frontiers in Cellular and Infection Microbiology,2019,9:48. [18] ANDES D,CRAIG W,NIELSEN L A,et al.In vivo pharmacodynamic characterization of a novel plectasin antibiotic NZ2114 in a murine infection model[J].Antimicrobial Agents and Chmotherapy,2009,53(7):3003-3009. [19] DE BREIJ A,RIOOL M,KWAKMAN P H,et al.Prevention of Staphylococcus aureus biomaterial-associated infections using a polymer-lipid coating containing the antimicrobial peptide OP-145[J].Journal of Controlled Release,2016,222:1-8. [20] CÉSAR F N E,FANY R,HANEY E.F,et al.Broad-spectrum anti-biofilm peptide that targets a cellular stress response[J].PLoS Pathogens,2014,10(5):e1004152. [21] YANG N,TENG D,MAO R Y,et al.A recombinant fungal defensin-like peptide-P2 combats multidrug-resistant Staphylococcus aureus and biofilms[J].Applied Microbiology and Biotechnology,2019,103(3):5193-5213. [22] WANG J,NONG X,ZHANG X,et al.Screening of anti-biofilm compounds from marine-derived fungi and the effects of secalonic acid D on Staphylococcus aureus biofilm[J].Journal of Microbiology and Biotechnology,2017,27(6),1078-1089. [23] HU Y,KAN Y,ZHANG Z,et al.New mutations of penicillin-binding proteins in Streptococcus agalactiae isolates from cattle with decreased susceptibility to penicillin[J].Microbial Drug Resistance,2018,24(8):1236-1241. [24] 赵飞,滕达,杨娜,等.抗菌肽NZ2114对多重耐药2型猪链球菌感染小鼠的治疗效果评价[J].中国畜牧兽医,2018,45(4):1089-1097. ZHAO F,TENG D,YANG N,et al.Evaluation of the therapeutic efficacy of antimicrobacterical peptide NZ2114 in mice infected with Streptococcus suis Serotype 2[J].China Animal Husbandry & Veterinary Medicine,2018,45(4):1089-1097.(in Chinese) [25] JIAO J,MAO R Y,TENG D,et al.In vitro and in vivo antibacterial effect of NZ2114 against Streptococcus suis type 2 infection in mice peritonitis models[J].AMB Express,2017,7(1):44-54. [26] OSTERGAARD C,SANDVANG D,FRIMODT-MOLLER N,et al.High cerebrospinal fluid (CSF) penetration and potent bactericidal activity in CSF of NZ2114,a novel plectasin variant,during experimental pneumococcal meningitis[J].Antimicrobial Agents and Chemotherapy,2009,53(4):1581-1585. [27] OSTERBERG L,BLASCHKE T.Adherence to medication[J].New England Journal of Medicine,2005,353(5):487-497. [28] 赵飞.Plectasin衍生肽对2型猪链球菌的抗菌机理研究及体内外药效学评价[D].天津:天津师范大学,2018. ZHAO F.Antibacterial mechanisms of plectasin derived peptides against Streptococcus suis type 2 and its pharmacodynamics evaluation in vivo and in vitro[D].Tianjin:Tianjin Normal University,2018.(in Chinese) [29] MELCHIOR M B,VAARKAMP H,FINK-GREMMELS J.Biofilms:A role in recurrent mastitis infec-tions?[J].The Veterinary Journal,2006,171(3):398-407. [30] ROBERTO R,IMMACULADA M.Biofilm formation by Streptococcus agalactiae:Influence of environmental conditions and implicated virulence factors[J].Frontiers in Cellular and Infection Microbiology,2015,5:6. [31] DEL P,JOSE L.Biofilm-related disease[J].Expert Review of Anti-infective Therapy,2018,16(1):51-65. [32] VENKATESAN N,PERUMAL G,DOBLE M.Bacterial resistance in biofilm-associated bacteria[J].Future Microbiology,2015,10(11):1743-1750. [33] HALL C W,MAH T F.Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria[J].FEMS Microbiology Reviews,2017,41(3):276-301. [34] ALGBURI A,COMITO N,KASHTANOV D,et al.Control of biofilm formation:Antibiotics and beyond[J].Applied and Environmental Microbiology,2016,83(6):e00165-17. [35] KRUKOWSKI H,SZYMANKIEWICZ M,LISOWSKI A.Slime production by Staphylococcus aureus strains isolated from cases of bovine mastitis[J].Polish journal of microbiology/Polskie Towarzystwo Mikrobiologów=The Polish Society of Microbiologists,2008,57(3):253-255. [36] FUENTENÚÑEZ C D L,KOROLIK V,BAINS M,et al.Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide[J].Antimicrobial Agents and Chemotherapy,2012,56(5):2696. [37] LEE J H,PARK J H,CHO H S,et al.Anti-biofilm activities of quercetin and tannic acid against Staphylococcus aureus[J].Biofouling,2013,29(5):491-499. |